Follicular Lymphoma Treatment Global Market Report 2024

The follicular lymphoma treatment market has grown strongly in recent years. It will grow from $2.83 billion in 2023 to $3.09 billion in 2024 at a compound annual growth rate (CAGR) of 9.0%. The expansion observed in the historical period can be ascribed to a rise in the incidence of follicular lymphoma, progress in cancer diagnostics, the growing aging population, ongoing clinical research and drug development, and collaborations in the field of oncology research.

The follicular lymphoma treatment market is expected to see strong growth in the next few years. It will grow to $4.2 billion in 2028 at a compound annual growth rate (CAGR) of 8.0%. The anticipated expansion in the forecast period can be linked to the adoption of personalized medicine approaches, advancements in immunotherapy, increased availability of innovative therapies, a heightened focus on improving the quality of life, and global initiatives promoting collaboration in the field of oncology. Noteworthy trends expected in the forecast period encompass engagement in clinical trials and research initiatives, exploration of epigenetic modifiers, improvements in radioimmunotherapy, the utilization of artificial intelligence (AI), and global collaborative efforts to enhance access to therapies.

The anticipated growth in the follicular lymphoma treatment market is expected to be propelled by the increasing prevalence of follicular lymphoma. Prevalence in this context refers to the overall number or percentage of individuals within a specific population diagnosed with follicular lymphoma at a given time or over a particular period. This rise can be attributed to factors such as the aging population, genetic predisposition, improved diagnostic techniques, and heightened awareness and screening. Follicular lymphoma treatment plays a crucial role in addressing the disease at various stages, contributing to the reduction of its prevalence and managing disease progression. The incidence of follicular lymphoma is on the rise, as highlighted by the American Cancer Society's January 2023 report, stating that non-Hodgkin lymphoma, including indolent follicular lymphoma, is the most common cancer in the US, accounting for approximately 4% of all cancers. The projection estimates around 80,550 new cases (44,880 in men and 35,670 in women) for both adults and children. Therefore, the increasing prevalence of follicular lymphoma serves as a driving force for the growth of the follicular lymphoma treatment market.

The growth of the follicular lymphoma treatment market is expected to be fueled by the rising aging population. The term "aging population" denotes a demographic shift characterized by a growing proportion of elderly individuals within a society over time. Follicular lymphoma treatment assumes a critical role in addressing the specific healthcare needs of the aging population, encompassing tailored treatment approaches, enhancing overall quality of life, and balancing treatment intensity. As of October 2022, the World Health Organization projected that by the year 2030, one in every six individuals globally would be 60 years old or older, with the population aged 60 and over expected to increase from 1 billion in 2020 to 1.4 billion. Furthermore, by 2050, the global population of individuals aged 60 and older is anticipated to double, reaching 2.1 billion. Hence, the rising aging population stands as a significant driver for the follicular lymphoma treatment market.

The follicular lymphoma treatment market is witnessing a significant trend of technological advancements in both diagnosis and treatment, presenting lucrative opportunities. Companies within this market are embracing advanced diagnostic and treatment approaches for follicular lymphoma to maintain their competitive positions. For example, in December 2022, Genentech Inc., a US-based biotechnology company, obtained FDA approval for Lunsumio - a novel bispecific antibody designed to treat relapsed or refractory follicular lymphoma. Lunsumio represents a new class of fixed-duration cancer treatment immunotherapy, providing a readily available and off-the-shelf treatment option without the need for patients to wait. The FDA approval was based on positive results from the Lunsumio Phase II GO29781 study involving individuals with extensively pretreated follicular lymphoma, particularly those at high risk of disease progression or unresponsive to prior treatments.

Major players in the follicular lymphoma treatment market are directing their efforts toward the development of innovative products, such as CAR-T cell therapy (Chimeric Antigen Receptor T-cell therapy). In May 2022, Novartis AG, a Switzerland-based pharmaceutical company, announced FDA approval for 'Kymriah,' the only CAR-T cell therapy approved to treat relapsed or refractory follicular lymphoma in both adult and pediatric settings. Kymriah, administered as a single infusion, offers a treatment option for patients dealing with follicular lymphoma or blood cancer.

In June 2022, Ipsen, a France-based biopharmaceutical company, acquired Epizyme Inc. for $247 million. This strategic acquisition enhances Ipsen's portfolio by incorporating a pipeline of therapeutic products, including commercially available drugs and treatments for follicular lymphoma. Epizyme Inc., a US-based clinical-stage biopharmaceutical and oncology drug developer, contributes to Ipsen's growth with its expertise in developing medicines for follicular lymphoma and other oncological conditions.

Major companies operating in the follicular lymphoma treatment market report are AbbVie Inc.,Celgene Corporation,Bayer AG,Bristol Myers Squibb Company,F. Hoffmann-La Roche Ltd.,Johnson and Johnson Services Inc.,GlaxoSmithKline plc,Novartis AG,Merck & Co. Inc.,EpiZyme Inc.,Boehringer Ingelheim GmbH,CTI BioPharma Corp.,Spectrum Pharmaceuticals Inc.,Seattle Genetics Inc.,Applied Molecular Genetics Inc.,Daiichi Sankyo Company Ltd.,Pfizer Inc.,Incyte Corporation,MorphoSys AG,Regeneron Pharmaceuticals Inc.,Eli Lilly and Company,Seagen Inc.,Takeda Pharmaceutical Company,Abbott Laboratories, Nordic Nanovector ASA,ADC Therapeutics SA,MEI Pharma Inc.,BeiGene Inc.,TG Therapeutics Inc.,Amgen Inc.,Dr. Reddy's Laboratories Ltd.

North America was the largest region in the follicular lymphoma treatment market in 2023. The regions covered in the follicular lymphoma treatment market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the follicular lymphoma treatment market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The primary types of treatments for follicular lymphoma include monoclonal antibodies, targeted therapy, chemotherapy, radiation therapy, stem cell transplant, alkylating agents, nucleoside analogues, anthracycline derivatives, and others. Monoclonal antibodies are laboratory-produced proteins designed to mimic the immune system's ability to target specific substances in the body. In follicular lymphoma treatment, they are utilized to target specific proteins on the surface of cancer cells, stimulating the immune system's response. Various products for follicular lymphoma treatment, such as tablets, capsules, injectables, and others, are administered through oral, parenteral, and other routes of administration. These treatments are provided in settings such as hospitals, oncology centers, ambulatory care centers, academic research institutes, and other healthcare facilities.

The follicular lymphoma treatment market research report provides follicular lymphoma treatment market statistics, including follicular lymphoma treatment industry global market size, regional shares, competitors with an follicular lymphoma treatment market share, detailed follicular lymphoma treatment market segments, market trends and opportunities, and any further data you may need to thrive in the follicular lymphoma treatment industry. This follicular lymphoma treatment market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The follicular lymphoma treatment market includes revenues earned by entities by providing drugs, medications, diagnostic devices, radiation therapy equipment, surgical instruments, and devices. Therapies that are used in the treatment of follicular lymphoma. The follicular lymphoma treatment market includes surgery, radiation therapy, chemotherapy, hormonal therapy, targeted therapy, and supportive care.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.


This product will be delivered within 3-5 business days.